Anatomy

Acute On Chronic Liver Failure (ACLF) Epidemiology Forecast Research Report 2021-2030 - ResearchAndMarkets.com

Monday, July 26, 2021 - 10:55am

The "Acute On Chronic Liver Failure (ACLF) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute On Chronic Liver Failure (ACLF) - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This 'Acute-On-Chronic Liver Failure ACLF)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Acute-On-Chronic Liver Failure (ACLF), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Acute-On-Chronic Liver Failure (ACLF) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Acute-On-Chronic Liver Failure (ACLF) epidemiology segmented as the Total Cases of Acute-On-Chronic Liver Failure (ACLF), Cases of Acute-On-Chronic Liver Failure (ACLF) by Grades, Organ Failure Associated with Acute-On-Chronic Liver Failure, Potential participating events of Acute-On-Chronic Liver Failure.

Acute On Chronic Liver Failure (ACLF) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com

Monday, July 26, 2021 - 10:33am

The "Acute On Chronic Liver Failure (ACLF) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acute On Chronic Liver Failure (ACLF) Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Acute-On-Chronic Liver Failure (ACLF)-Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the Acute-On-Chronic Liver Failure (ACLF), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The epidemiology segment also provides the Acute-on-chronic liver failure (ACLF) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Acute-On-Chronic Liver Failure (ACLF) market in 7MM is expected to change in the study period 2018-2030.

Back-Tooth-School Effort Reminds Parents and Caregivers that Good Grades Begin with a Dental-Check-Up

Monday, July 26, 2021 - 5:30pm

A dental check-up should be on every familys back to school checklist because a childs oral health affects their overall health.

Key Points: 
  • A dental check-up should be on every familys back to school checklist because a childs oral health affects their overall health.
  • Healthy teeth not only help children eat, speak, and sleep better, but they also help them to perform better in school.
  • Parents, caregivers, and community partners across the state will have resources to help them better understand the vital role a dental check-up plays in school readiness.
  • All children should begin seeing a dentist by the time their first tooth comes in or by their first birthday.

Nutra Pharma Files Updated Provisional Patent for Nerve Agent Counter Measures

Friday, July 23, 2021 - 2:14pm

"We originally announced this project in early 2018, stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.

Key Points: 
  • "We originally announced this project in early 2018, stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma.
  • Nerve agents are identified as a class of phosphorus-containing organic chemicals (organophosphates) that may disrupt the transfer of messages to organs through the nerves.
  • These same receptors are the target of Nutra Pharmas drugs, which may block the action of the nerve agents or minimize the damage that they may cause.
  • Scientific publications have demonstrated that native and modified neurotoxins can protect nerve cells from early cell death.

NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Thursday, July 22, 2021 - 9:05pm

Completing enrollment in CATALINA is an important milestone for NGM and the patients with geographic atrophy that we hope to serve.

Key Points: 
  • Completing enrollment in CATALINA is an important milestone for NGM and the patients with geographic atrophy that we hope to serve.
  • We are highly encouraged by the programs progress to date and for the potential of NGM621 to change the disease trajectory for geographic atrophy patients.
  • The Phase 2 CATALINA study enrolled a total of 320 patients with geographic atrophy, more than the originally planned 240 patients.
  • The Phase 2 CATALINA study enrolled 320 patients diagnosed with geographic atrophy in one or both eyes.

Black Women's Health Advocates Applaud Legislation to Address the Uterine Fibroid Crisis

Friday, July 23, 2021 - 12:26am

"Uterine fibroids are a health threat that urgently requires research, resources, and improved treatment options."

Key Points: 
  • "Uterine fibroids are a health threat that urgently requires research, resources, and improved treatment options."
  • "Uterine fibroids are a health threat that urgently requires research, community resources, and improved treatment options that preserve fertility.
  • BWHI supports this legislation because it will increase funding for uterine fibroid research and lead to new evidence-based treatments and cures for women of color."
  • "There is much more work to be done to address the uterine fibroid crisis.

Bloom Beauty Essence® – Radiant Skin Combats Everything that Attacks Your Skin

Thursday, July 22, 2021 - 5:17pm

A German pharmaceutical company, R-Pharm, has created Bloom Beauty Essence which provides day and night protection through a superfood supplement and collagen drink to make your skin radiant.

Key Points: 
  • A German pharmaceutical company, R-Pharm, has created Bloom Beauty Essence which provides day and night protection through a superfood supplement and collagen drink to make your skin radiant.
  • Steiner-Kienzler said R-Pharm developed Bloom Beauty Essence products to reduce wrinkles, increase skin resistance and tighten your bodys skin.
  • Bloom Beauty Essence Night Spa naturally rejuvenates your skin by using superfoods, such as pomegranate and gluten-free wheat extracts, Steiner-Kienzler said.
  • Bloom Beauty Essence Skin Care Drink With Collagen, which provides an extra boost during the day,comes in regular and low-calorie versions.

Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis / Bladder Pain Syndrome at the Upcoming American Urological Association Conference (AUA) in September 2021

Thursday, July 22, 2021 - 4:11pm

IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.

Key Points: 
  • IC/BPS and its associated pain significantly affects quality of life, including loss of work, and is associated with suicidal rates five-to-seven times the national average.
  • Our preliminary results should be further confirmed in the upcoming Phase IIa trial, said Dan Touitou, Chief Executive Officer of Trigone Pharma.
  • The data has also prompted us to evaluate the safety and efficacy in overactive bladder and renal colic patients.
  • Trigone Pharma is aiming to restore the quality of life for patients suffering from bladder diseases that affect populations with unmet medical needs.

2021 Report on Retinal Degeneration Drugs in Development - ResearchAndMarkets.com

Thursday, July 22, 2021 - 3:11pm

The "Retinal Degeneration (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinal Degeneration (Ophthalmology) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive information on the therapeutics under development for Retinal Degeneration, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Degeneration and features dormant and discontinued projects.
  • The report reviews key players involved in the development of Retinal Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.

Global Graves Ophthalmopathy Market to 2030 - Insight, Epidemiology and Market Forecasts - ResearchAndMarkets.com

Thursday, July 22, 2021 - 2:40pm

The "Graves Ophthalmopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Graves Ophthalmopathy - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Graves Ophthalmopathy market report provides current treatment practices, emerging drugs, Graves Ophthalmopathy market share of the individual therapies, current and forecasted Graves Ophthalmopathy market Size from 2017 to 2030 segmented by seven major markets.
  • The Graves Ophthalmopathy market report gives a thorough understanding of the Graves Ophthalmopathy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
  • The Graves Ophthalmopathy epidemiology division provide insights about historical and current Graves Ophthalmopathy patient pool and forecasted trend for every seven major countries.